Gothenburg-based Elicera Therapeutics develops a portfolio of drug candidates helping the immune system in the fight against various forms of cancer. The share is about to be listed on Nasdaq First North Growth Market, and the company aims to raise 52 MSEK to drive the development of its drug candidates and the technology platform iTANK further. At today’s BioStock Live, CEO Jamal El-Mosleh will present the company, give insight to the development portfolio and comment on the issue.
Elicera Therapeutics is presented by CEO Jamal El-Mosleh. See the presentation here at 10:00:
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
Expand your understanding of new markets, striking global partnerships and attracting international capital. Find new opportunities and learn how to...
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
